Sumitomo Mitsui DS Asset Management Company Ltd Acquires 871 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 26,388 shares of the medical equipment provider’s stock after buying an additional 871 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Hologic were worth $1,902,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. FMR LLC grew its holdings in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. Nordea Investment Management AB grew its stake in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares during the period. Swedbank AB increased its position in Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares during the period. Finally, Barclays PLC boosted its holdings in Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after acquiring an additional 231,578 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of Hologic stock opened at $65.24 on Tuesday. The firm has a market capitalization of $14.73 billion, a P/E ratio of 20.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52. The business’s fifty day simple moving average is $72.06 and its 200 day simple moving average is $77.67. Hologic, Inc. has a 12 month low of $63.62 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on HOLX. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. UBS Group upped their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Stephens reiterated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Finally, Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Hologic currently has an average rating of “Moderate Buy” and an average price target of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.